Pengfei Liu

Prof. Pengfei Liu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Life Sciences
Verified
Journal Article
Closed access
YCYaodong Chen
Yaodong Chen
JNJiamei Niu
Jiamei Niu
LLLulu Li
Lulu Li
ZLZizhuo Li
Zizhuo Li
JJJian Jiang
Jian Jiang
WCWu Chen
Wu Chen

14 November 2022 in Life Sciences
Verified
Journal Article
Closed access
XCXi Chen
Xi Chen
MZMingwei Zhu
Mingwei Zhu
XZXiaomeng Zou
Xiaomeng Zou
YMYingxuan Mao
Yingxuan Mao
JNJiamei Niu
Jiamei Niu
PLPengfei Liu
Pengfei Liu

28 January 2022 in Life Sciences
Verified
Journal Article
Closed access
MZMingwei Zhu
Mingwei Zhu
JNJiamei Niu
Jiamei Niu
JJJian Jiang
Jian Jiang
TDTianxiu Dong
Tianxiu Dong
YCYaodong Chen
Yaodong Chen
PLPengfei Liu
Pengfei Liu

14 September 2022 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
YSYexin Su
Yexin Su
HZHongyue Zhao
Hongyue Zhao
PLPengfei Liu
Pengfei Liu
LZLinhan Zhang
Linhan Zhang
YJYuying Jiao
Yuying Jiao
FPFu PENG
Fu PENG

1 May 2024 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
XZXinyu Zhu
Xinyu Zhu
YSYing Shi
Ying Shi
JLJianxiu Lian
Jianxiu Lian
HSHonghu Shen
Honghu Shen
LLLulu Li
Lulu Li
PLPengfei Liu
Pengfei Liu
Background: Sudden cardiac death (SCD) represents the most severe complication of hypertrophic cardiomyopathy (HCM). The risk stratification of SCD in patients with HCM remains a subject of ongoing debate, and the utility of left atrial (LA) and left ventricular (LV) myocardial strain for risk stratification of also SCD remains uncertain. Through use of feature-tracking cardiac magnetic resonance (FT-CMR), this study aimed to investigate the attenuation of LA and LV strain in HCM and to assess their predictive value in SCD. Methods: This retrospective and cross-sectional study included patients with HCM who underwent 3.0 T cardiac magnetic resonance (CMR) at a single institution. Feature-tracking strain analysis was conducted to obtain the strain rate (SR) and LV strain and to evaluate LV function. LA strain was measured during different functional phases including left atrial reservoir strain (LARS), LA conduit strain (LACS), and LA booster strain. All patients were categorized into high- and low-risk groups for SCD as defined by the 2020 American Heart Association/American College HCM implantable cardioverter defibrillator class of recommendation algorithm. Comparison between the two groups was conducted using the independent samples t test and the nonparametric rank sum test. Multivariate logistic regression analysis was performed to further identify the factors influencing SCD risk in HCM. Results: Compared with those in the low-risk group, patients in the high-risk group had lower left ventricular ejection fraction (LVEF), LV stroke volume index (LVSVI), and LA stroke volume index (LASVI) but a higher LV end-systolic volume index (LVESVI), LV maximum wall thickness, and late gadolinium enhancement (LGE) (P<0.001). LV strain, SR, and LA strain all showed significant differences between the high- and low-risk groups (LARS: P=0.04; LACS: P=0.02; all other P values <0.001). The LV global circumferential strain (LVGCS) had a strong negative correlation with LVEF in patients with HCM (r=–0.76; P<0.001). Multivariate analysis showed that LV global radial strain (LVGRS) and LARS could be used for categorizing the patients into the high-risk group [LVGRS: odds ratio (OR) =0.69; 95% confidence interval (CI): 0.55–0.87, P<0.001; LARS: OR =1.39; 95% CI: 1.02–1.90, P=0.03]. The combined LVGRS-LARS model exhibited a superior diagnostic value for high risk of SCD [area under the curve (AUC) =0.95; 95% CI: 0.90–1.00; P<0.001] compared to LARS alone (AUC =0.63; 95% CI: 0.51–0.76; P=0.04). Conclusions: LA and LV strain measured by FT-CMR can accurately identify those patients with HCM at a high risk of SCD. This approach may prove considerably value in guiding early therapeutic intervention with implantable cardioverter-defibrillators (ICDs) to prevent adverse clinical outcomes.

1 January 2021 in DNA and Cell Biology
Verified
Journal Article
Closed access
YSYing Shi
Ying Shi
JJJian Jiang
Jian Jiang
YCYingzhe Cui
Yingzhe Cui
YCYaodong Chen
Yaodong Chen
TDTianxiu Dong
Tianxiu Dong
PLPengfei Liu
Pengfei Liu
Glioblastoma multiforme (GBM) is characterized by diffuse infiltration of the brain, active regional recurrence, low cure proportion, and limited chemotherapy efficiency. MutS homolog 6 (MSH6) is a component of the mismatch repair system related to the oncogenesis, tumor evolution, and recurrence of GBM. The impact of MSH6 upregulation on the tumor microenvironment (TME) of GBM and the feasibility of MSH6 as a potential target to improve the prognosis remain unknown. The expression of MSH6 at mRNA level indicated that MSH6 expressed higher in GBM tissues than that in normal ones. The transwell assay and expression levels of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) suggested that the capability of invasion and migration in U251-MSH6 was more stubborn. The intracranial tumor model was established with nude mice to further explore in vivo. The time-weight curve, overall survival, tumor volumes, expression levels of MMP-2 and MMP-9 in tissue, and hematoxylin and eosin staining all indicated that MSH6 had a positive effect on metastasis. The expression levels of related proteins suggested that the hypoxia TME induced by MSH6 may promote metastasis via epithelial to mesenchymal transition, stemness, and angiogenesis progress. MSH6 is an overexpressed oncogene in human GBM tissues, which accelerated metastasis by regulating hypoxia inducible factor-1A (HIF1A) to form a hypoxic TME in GBM. The MSH6 was a vital marker of GBM, making it a promising therapeutic target.